Columvi combo in DLBCL, while AnaptysBio's ANB032 fails in atopic dermatitis. Essential Pharma gets €1.2B financing deal.
Hosted on MSN44m
AnaptysBio Stock Down as Eczema Study Fails to Meet GoalsShares of AnaptysBio, Inc. ANAB, a clinical-stage biotechnology company, plunged 32.8% on Dec. 11 after it announced that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback